Non-Small-Cell Lung Cancer | Unmet Need | US/EU | 2016
Metastatic squamous-cell NSCLC is an incurable disease associated with a dismal 5 year OS of <5%; treatments delivering improvements to survival are therefore a key treatment goal in this disease. Despite recent approvals of Portrazza, Opdivo and Keytruda for metastatic squamous-cell NSCLC, surveyed oncologists highlight that novel therapies with improved clinical efficacy are still an area of high unmet need. This report investigates key drivers of prescribing in squamous-cell NSCLC, and identifies key areas of unmet need in the indication.
Related Market Assessment Reports
Report
Systemic Lupus Erythematosus – Access & Reimbursement – Access & Reimbursement – Systemic Lupus Erythematosus (US)
The U.S. systemic lupus erythematosus (SLE) therapy market is largely genericized and off-label. With the exception of GSK’s Benlysta, the firstagents approved for the indication in almost 60…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Heart failure with reduced ejection fraction (HFrEF) occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Drug treatment for HFrEF is well established and supported by…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) occurs when the left ventricular ejection fraction (LVEF) is 50% or more. Even though physicians’ understanding of the disease’s…
